Loading people...
Bert Vogelstein is a Venture Partner at Catalio Capital Management and the Co-Director of the Ludwig Center at Johns Hopkins University in Baltimore, Maryland. He earned his MD from the Johns Hopkins University School of Medicine and a BA from the University of Pennsylvania. As a pioneering researcher in cancer genetics, he has co-founded multiple molecular diagnostics companies, including Exact Sciences and Personal Genome Diagnostics, which Labcorp acquired for $575 million. He additionally co-founded Thrive Earlier Detection, an early cancer detection startup that Exact Sciences subsequently acquired for $2.15 billion in 2021. A recipient of the 2013 Breakthrough Prize in Life Sciences, he serves on the scientific advisory boards for Sysmex and Morphotek-Eisai. His current professional focus centers on bridging academic oncology research with biotechnology venture capital investments to commercialize novel early cancer detection technologies.
Dr. Bert Vogelstein is a highly respected Venture Partner at Catalio Capital, a leading multi-strategy healthcare investment firm. In this pivotal role, Dr. Vogelstein applies his profound scientific acumen and extensive experience in medical research to identify and evaluate promising investment opportunities within the life sciences and healthcare sectors. His contributions are instrumental in guiding Catalio Capital's strategy, particularly in areas poised for significant scientific and commercial breakthroughs.
Dr. Vogelstein's investment focus areas at Catalio Capital are deeply rooted in his illustrious career as a scientist. He is particularly interested in oncology, genomics, molecular diagnostics, and novel therapeutic platforms that address unmet medical needs. His expertise allows the firm to pinpoint companies developing truly innovative solutions, from early-stage research to clinical development, ensuring investments are aligned with the most impactful scientific advancements. His insights help Catalio Capital navigate the complex landscape of biotech and healthcare, identifying ventures with the potential for transformative impact on human health.
Before joining Catalio Capital, Dr. Vogelstein established himself as one of the most influential figures in cancer research globally. He is a Professor of Oncology and Pathology at the Johns Hopkins University School of Medicine and an Investigator at the Howard Hughes Medical Institute. His groundbreaking work on the molecular basis of colorectal cancer revolutionized our understanding of cancer development, establishing the multi-step model of carcinogenesis. He was a pioneer in identifying specific genetic mutations responsible for various cancers, laying the foundation for modern cancer genetics and personalized medicine. His discoveries have led to significant advancements in cancer diagnosis, prognosis, and treatment strategies, impacting countless lives worldwide. His career is marked by numerous prestigious awards and recognitions for his scientific contributions.
While specific notable investments led by Dr. Vogelstein in his Venture Partner capacity are typically proprietary to Catalio Capital, his influence is undoubtedly felt across the firm's portfolio. His guidance helps validate the scientific merit of potential investments, ensuring that Catalio Capital backs companies with robust scientific foundations and genuine potential for clinical success. His involvement signals a strong commitment to scientific rigor and innovation, making Catalio Capital an attractive partner for groundbreaking healthcare startups. His unique blend of scientific genius and strategic foresight makes him an invaluable asset to the Catalio Capital team and the broader healthcare investment community.
Bert Vogelstein is a world-renowned cancer researcher and a Venture Partner at Catalio Capital. He is celebrated for his groundbreaking work on the molecular basis of cancer and now applies his scientific expertise to guide healthcare and biotech investments.
As a Venture Partner at Catalio Capital, Bert Vogelstein focuses on investments in oncology, genomics, molecular diagnostics, and novel therapeutic platforms. His expertise helps identify innovative solutions in the life sciences and healthcare sectors.
Bert Vogelstein works as a Venture Partner at Catalio Capital, a multi-strategy healthcare investment firm. He is also a Professor of Oncology and Pathology at Johns Hopkins University School of Medicine and an Investigator at the Howard Hughes Medical Institute.
